Wire · regulatory
FDA moves to yank Salerno's liquid cholesterol drug approval on missing reports
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The FDA is moving to withdraw approval for Salerno Pharmaceuticals' FloLipid cholesterol drug due to the company's failure to submit required annual reports and respond to FDA requests. Salerno has until December 18, 2026, to request a hearing to defend the drug's approval.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You must elevate compliance tracking as FDA enforcement can revoke product approval quickly, blocking market access. Missing regulatory steps puts your drug at immediate risk of withdrawal, triggering urgent defence or exit moves.
◆ Coverage
3 sources · 18 Nov 2026
◆ Related on Wire
◆ Topics